FIG
VIR icon

Freed Investment Group’s Vir Biotechnology VIR Stock Holding History

Freed Investment Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$218K Hold
5,000
– – 0.17% 15
2021
Q2 		$236K Hold
5,000
– – 0.18% 14
2021
Q1 		$256K Buy
+5,000
New +$269K 0.22% 13

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freed Investment Group's VIR Position: Q3 2021 in Review

Freed Investment Group held its Vir Biotechnology (VIR) position steady in Q3 2021 at 5,000 shares worth $218K. The position accounts for 0.17% of the portfolio, ranked #15.

Freed Investment Group first reported a position in VIR in Q1 2021 and has held it in 3 quarters since. The position peaked at $256K in Q1 2021. 175 funds tracked by Wall St. Rank hold VIR as of Q3 2021.

  • Freed Investment Group held 5,000 shares of Vir Biotechnology worth $218K as of Q3 2021.
  • Freed Investment Group left its Vir Biotechnology share count unchanged in Q3 2021.
  • Vir Biotechnology made up 0.17% of Freed Investment Group's portfolio in Q3 2021, its #15 holding.
  • Freed Investment Group first reported a position in Vir Biotechnology in Q1 2021 and has held it in 3 quarters since.
  • Freed Investment Group's Vir Biotechnology position peaked at $256K in Q1 2021.
  • 175 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2021.

Based on Freed Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.